• Vaccine Name: S. pyogenes FBP54 Protein Vaccine
• Target Pathogen: Streptococcus pyogenes
• Target Disease: Group A streptococcal infections, Strep throat, Scarlet fever
• Vaccine Ontology ID: VO_0004055
• Type: Subunit vaccine
• Status: Research
• Antigen: Recombinant FBP54 protein
• fbp54 gene engineering:
  • Type: Recombinant protein preparation
  • Description:
  • Detailed Gene Information: Click Here.
• Adjuvant:
  • Adjuvant name:
  • VO adjuvant ID: VO_0000143
• Immunization Route: Orally

Mouse Response

• Host Strain: BALB/c
• Vaccination Protocol: Mice were orally immunized with cholera toxin (CT; 10 μg)-FBP54 (10 μg) or CT (10 μg)-PBS by using an intubation needle. Immunization was performed four times, on days 0, 14, 28, and 42 (Kawabata et al., 2001).
• Challenge Protocol: Actively immunized mice were intraperitoneally challenged with an appropriate number of CFU of S. pyogenes SSI-1 (M3), SSI-9 (M1), or S42 (M12) on day 51 following immunization (Kawabata et al., 2001).
• Efficacy: Mice subcutaneously or orally immunized with FBP54 survived significantly longer following the challenge with S. pyogenes than did nonimmunized mice (Kawabata et al., 2001).
• Host IgA response
  • Description: An enzyme-linked immunosorbent assay revealed that antigen-specific IgG antibodies were induced in the sera of immunized mice, while high salivary levels of IgA antibodies were detected after oral and nasal immunizations. Nonimmunized control groups did not show any detectable humoral immune responses to FBP54 in sera (Kawabata et al., 2001).
  • Detailed Gene Information: Click Here.
• Host IgG response
  • Description: An enzyme-linked immunosorbent assay revealed that antigen-specific IgG antibodies were induced in the sera of immunized mice, while high salivary levels of IgA antibodies were detected after oral and nasal immunizations. Nonimmunized control groups did not show any detectable humoral immune responses to FBP54 in sera (Kawabata et al., 2001).
  • Detailed Gene Information: Click Here.